Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

This statement examines the cardiovascular complications of diabetes mellitus and considers opportunities for their prevention. These complications include coronary heart disease (CHD), stroke, peripheral arterial disease, nephropathy, retinopathy, and possibly neuropathy and cardiomyopathy. Because of the aging of the population and an increasing prevalence of obesity and sedentary life habits in the United States, the prevalence of diabetes is increasing. Thus, diabetes must take its place alongside the other major risk factors as important causes of cardiovascular disease (CVD). In fact, from the point of view of cardiovascular medicine, it may be appropriate to say, “diabetes is a cardiovascular disease.” The most prevalent form of diabetes mellitus is type 2 diabetes. This disorder typically makes its appearance later in life. The underlying metabolic causes of type 2 diabetes are the combination of impairment in insulin-mediated glucose disposal (insulin resistance) and defective secretion of insulin by pancreatic β-cells. Insulin resistance develops from obesity and physical inactivity, acting on a substrate of genetic susceptibility.1 2 Insulin secretion declines with advancing age,3 4 and this decline may be accelerated by genetic factors.5 6 Insulin resistance typically precedes the onset of type 2 diabetes and is commonly accompanied by other cardiovascular risk factors: dyslipidemia, hypertension, and prothrombotic factors.7 8 The common clustering of these risk factors in a single individual has been called the metabolic syndrome. Many patients with the metabolic syndrome manifest impaired fasting glucose (IFG)9 even when they do not have overt diabetes mellitus.10 The metabolic syndrome commonly precedes the development of type 2 diabetes by many years11 ; of great importance, the risk factors that constitute this syndrome contribute independently to CVD risk. Recently, new criteria have been accepted for the diagnosis of diabetes.9 The upper threshold of fasting plasma glucose for the …

[1]  [Kidney diseases in diabetes in children]. , 1963, La Semana medica.

[2]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.

[3]  A. Grishman,et al.  New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.

[4]  S. Ahmed,et al.  Evidence for cardiomyopathy in familial diabetes mellitus. , 1977, The Journal of clinical investigation.

[5]  S. Rostand,et al.  Racial differences in the incidence of treatment for end-stage renal disease. , 1982, The New England journal of medicine.

[6]  C. Mogensen,et al.  The Stages in Diabetic Renal Disease: With Emphasis on the Stage of Incipient Diabetic Nephropathy , 1983, Diabetes.

[7]  T. Regan Congestive heart failure in the diabetic. , 1983, Annual review of medicine.

[8]  K. Minaker,et al.  Characterization of the insulin resistance of aging. , 1983, The Journal of clinical investigation.

[9]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[10]  S. Lillioja,et al.  Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. , 1984, The Journal of clinical investigation.

[11]  F. Marcus,et al.  Prognosis of patients with diabetes mellitus after acute myocardial infarction. , 1984, The American journal of cardiology.

[12]  C. Mogensen,et al.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. , 1984, The New England journal of medicine.

[13]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[14]  R. Nesto,et al.  Asymptomatic myocardial ischemia in diabetic patients. , 1986, The American journal of medicine.

[15]  W. Knowler,et al.  Effect of Proteinuria on Mortality in NIDDM , 1988, Diabetes.

[16]  T. Farag Familial hypercholesterolemia. , 1988, Journal of the Royal Society of Medicine.

[17]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[18]  H. Parving,et al.  Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes , 1988, British medical journal.

[19]  W C Willett,et al.  Low-density lipoprotein subclass patterns and risk of myocardial infarction. , 1988, JAMA.

[20]  T. Regan,et al.  Cardiac disease in diabetes. , 1989, Postgraduate medicine.

[21]  D. Singer,et al.  Diabetic Myocardial Infarction: Interaction of Diabetes With Other Preinfarction Risk Factors , 1989, Diabetes.

[22]  P. Savage,et al.  Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. , 1989, The New England journal of medicine.

[23]  P. Savage,et al.  Role of Cardiovascular Risk Factors in Prevention and Treatment of Macrovascular Disease in Diabetes , 1989, Diabetes Care.

[24]  A. Jaffe,et al.  The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. , 1989, Journal of the American College of Cardiology.

[25]  S. Factor,et al.  A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. , 1990, Circulation.

[26]  J. Gillaspy,et al.  Racial differences in the incidence of end-stage renal disease in types I and II diabetes mellitus. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  A. Krolewski,et al.  Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. , 1990, Annals of internal medicine.

[28]  R. Campbell,et al.  Coronary heart disease in high-risk populations: lessons from Finland. , 1990, European heart journal.

[29]  M. King,et al.  Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. , 1990, Circulation.

[30]  J. Sowers Insulin resistance and hypertension , 1990, Molecular and Cellular Endocrinology.

[31]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[32]  J. Briggs,et al.  Outcome of renal replacement treatment in patients with diabetes mellitus. , 1990, BMJ.

[33]  Standards of Medical Care for Patients With Diabetes Mellitus , 1991, Diabetes Care.

[34]  K. Derfler,et al.  Renal replacement therapy in type 2 diabetic patients: 10 years' experience. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  A. Zwinderman,et al.  Increased morbidity and mortality in patients with diabetes mellitus after kidney transplantation as compared with non-diabetic patients. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[36]  Richard A. Kronmal,et al.  Distribution and Correlates of Sonographically Detected Carotid Artery Disease in the Cardiovascular Health Study , 1992, Stroke.

[37]  R J Jarrett,et al.  Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. , 1992, Kidney international.

[38]  A. Fitzgerald,et al.  Prospective Study of Microalbuminuria as Predictor of Mortality in NIDDM , 1992, Diabetes.

[39]  R. Nesto,et al.  Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. , 1992, Journal of the American College of Cardiology.

[40]  J. Sowers,et al.  Insulin Resistance in Hypertension: A Focused Review , 1993, The American journal of the medical sciences.

[41]  E. Barrett-Connor,et al.  Prevalence of Cardiovascular and Renal Complications in Older Adults With Normal or Impaired Glucose Tolerance or NIDDM: A population-based study , 1993, Diabetes Care.

[42]  B. Kasiske,et al.  Effect of Antihypertensive Therapy on the Kidney in Patients with Diabetes: A Meta-Regression Analysis , 1993, Annals of Internal Medicine.

[43]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[44]  L. Agodoa,et al.  The excess risk of treated end-stage renal disease in blacks in the United States. , 1993, Journal of the American Society of Nephrology : JASN.

[45]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[46]  M. Lishner,et al.  Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.

[47]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[48]  Richard Barnett,et al.  Diabetes mellitus. , 1993, The Medical journal of Australia.

[49]  V. Brezinka,et al.  Coronary heart disease risk factors in women. , 1994, European heart journal.

[50]  D. Bell,et al.  Stroke in the diabetic patient. , 1994, Diabetes care.

[51]  A Fournier,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.

[52]  Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[53]  L. Wilkins National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). , 1994 .

[54]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[55]  A. Folsom,et al.  Relation of Carotid Artery Wall Thickness to Diabetes Mellitus, Fasting Glucose and Insulin, Body Size, and Physical Activity , 1994, Stroke.

[56]  G. Reaven Insulin Resistance and Coronary Heart Disease , 1995 .

[57]  V. Fuster,et al.  Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.

[58]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[59]  S. Grundy,et al.  Relationships of generalized and regional adiposity to insulin sensitivity in men. , 1995, The Journal of clinical investigation.

[60]  S. Hunt,et al.  Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel? , 1996, Current opinion in lipidology.

[61]  J. Herlitz,et al.  Mortality and Morbidity in Diabetic and Nondiabetic Patients During a 2-Year Period After Coronary Artery Bypass Grafting , 1996, Diabetes Care.

[62]  D L Rothman,et al.  Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. , 1996, The New England journal of medicine.

[63]  G. Reaven,et al.  Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system. , 1996, The New England journal of medicine.

[64]  J. Willerson Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. , 1996, Circulation.

[65]  M. Austin,et al.  Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes , 1996, Current opinion in lipidology.

[66]  J. Tobin,et al.  The effect of age on insulin resistance and secretion: a review. , 1996, Seminars in nephrology.

[67]  D. Faxon,et al.  Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1996, Circulation.

[68]  J. Pugh,et al.  Non-Insulin-Dependent Diabetes Mellitus in Minorities in the United States , 1996, Annals of Internal Medicine.

[69]  L. Kuller,et al.  Coronary artery disease in IDDM. Gender differences in risk factors but not risk. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[70]  P. Bennett,et al.  Kidney Diseases in Diabetes , 1996 .

[71]  K. Sørensen,et al.  Incipient Cardiomyopathy in Young Insulin‐dependent Diabetic Patients: A Seven‐year Prospective Doppler Echocardiographic Study , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[72]  S M Grundy,et al.  Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. , 1997, Circulation.

[73]  G. Dagenais,et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Circulation.

[74]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[75]  M. Fantone,et al.  Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.

[76]  Detection The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[77]  Impaired Glucose Tolerance, Insulin Resistance and Cardiovascular Disease , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[78]  E. Antman,et al.  ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). , 2002, Circulation.

[79]  E. Kraegen,et al.  PATHOGENESIS OF THE INSULIN RESISTANCE SYNDROME (SYNDROME X) , 1997, Clinical and experimental pharmacology & physiology.

[80]  M. Hammami Diabetes Mellitus: A Fundamental and Clinical Text , 1997 .

[81]  T. B. Investigators,et al.  Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) , 1997, Circulation.

[82]  J. Spertus,et al.  Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. , 1997, Circulation.

[83]  R. Weinshilboum,et al.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.

[84]  I. Ockene,et al.  Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. , 1997, Circulation.

[85]  D. Cook,et al.  Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in south London , 1997, Heart.

[86]  M. Walker,et al.  Multiple metabolic abnormalities in normal glucose tolerant relatives of NIDDM families , 1997, Diabetologia.

[87]  H. Mcgill,et al.  Determinants of atherosclerosis in the young , 1998 .

[88]  D. Levy,et al.  Prediction of coronary heart disease using risk factor categories. , 1998, Circulation.

[89]  C. Spurr,et al.  Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.

[90]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[91]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[92]  B. Neuschwander‐Tetri,et al.  Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report , 1998, Annals of Internal Medicine.

[93]  P. McKeigue,et al.  Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[94]  Terminal Dehydration as an Alternative to Physician-Assisted Suicide , 1998 .

[95]  S M Grundy,et al.  Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. , 1998, Circulation.

[96]  M. Trovati,et al.  Insulin, insulin resistance and platelet function: similarities with insulin effects on cultured vascular smooth muscle cells , 1998, Diabetologia.

[97]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[98]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[99]  G. Riccardi,et al.  Plasma Fibrinogen: A New Factor of the Metabolic Syndrome: A population-based study , 1998, Diabetes Care.

[100]  Prevalence of diagnosed diabetes among American Indians/Alaskan Natives--United States, 1996. , 1998, MMWR. Morbidity and mortality weekly report.

[101]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[102]  J. Gerich,et al.  The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. , 1998, Endocrine reviews.

[103]  M. Laakso,et al.  Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. , 1997, Atherosclerosis.

[104]  H. Mcgill,et al.  Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. , 1998, The American journal of cardiology.

[105]  S. Kahn,et al.  Human aging is associated with parallel reductions in insulin and amylin release. , 1998, The American journal of physiology.

[106]  S. Dinneen,et al.  HIV Testing in Pregnant Women , 1998, Annals of Internal Medicine.

[107]  S. Grundy Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. , 1998, The American journal of cardiology.

[108]  Grundy,et al.  Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue , 1998, Journal of internal medicine.

[109]  S. Haffner Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[110]  P. Savage,et al.  Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. , 1998, American journal of epidemiology.

[111]  R. Baumgartner,et al.  Prevalences of Type 2 Diabetes, the Insulin Resistance Syndrome, and Coronary Heart Disease in an Elderly, Biethnic Population , 1998, Diabetes Care.

[112]  American Diabetes Association: clinical practice recommendations 1999. , 1999, Diabetes care.

[113]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[114]  P. Wilson,et al.  Diabetes mellitus and coronary heart disease. , 2001, Endocrinology and metabolism clinics of North America.